Kristen N Ganjoo

Clinical Trials

• Not Recruiting Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
• Not Recruiting Phase II Study of Bexxar in Relapsed/Refractory Diffuse Large Cell Lymphoma
• Not Recruiting Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma
• Not Recruiting Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
• Recruiting Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma
• Not Recruiting Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma
• Recruiting Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies
• Not Recruiting Linsitinib To Treat Patients With Gastrointestinal Stromal Tumors
• Recruiting A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
• Not Recruiting Trial of Dasatinib in Advanced Sarcomas
• Not Recruiting Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
• Recruiting Paclitaxel + Bevacizumab (Avastin®) for the Treatment of Metastatic or Unresectable Angiosarcoma
• Recruiting A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
• Not Recruiting CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer
• Not Recruiting High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
• Not Recruiting Safety Study of Denosumab in Subjects With Recurrent or Unresectable Giant Cell Tumor of Bone
• Not Recruiting A Study of R1507 in Patients With Recurrent or Refractory Sarcoma.
• Not Recruiting A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
• Not Recruiting Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
• Not Recruiting Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma
• Not Recruiting Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
• Not Recruiting Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma
• Not Recruiting Clinical Trial of PXD101 in Patients With T-Cell Lymphomas
• Not Recruiting Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia
• Not Recruiting Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT
• Not Recruiting S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
• Not Recruiting Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma
• Not Recruiting Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
• Not Recruiting Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma
• Not Recruiting Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer (Excluding Squamous Cell)
• Not Recruiting A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
• Not Recruiting Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
• Not Recruiting A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
• Not Recruiting A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma
• Not Recruiting Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
• Not Recruiting Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
• Not Recruiting Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma
• Not Recruiting Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma
• Not Recruiting Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma
• Not Recruiting Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma
• Not Recruiting Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms
• Not Recruiting Study of Bexxar Combined With External Beam Radiation Therapy for Patients With Relapsed, Bulky Non-Hodgkin's Lymphoma
• Recruiting Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
• Recruiting Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma